PMID: 20120581Sep 1, 1981Paper

A case-referent study on acute myeloid leukemia, background radiation and exposure to solvents and other agents

Scandinavian Journal of Work, Environment & Health
U FlodinO Axelson

Abstract

The effect of potential risk factors for acute myeloid leukemia was evaluated in a case-referent study encompassing 42 cases and 244 referents, all deceased. Information on exposure was obtained with questionnaires mailed to the next of kin. Particularly the effect of background radiation was evaluated, as assessed with a gamma radiation index weighing the time spent outdoors and indoors and considering the building material (stone, wood, etc.) in the homes and the workplaces of the subjects. Especially between the ages of 20 and 49 a, to some extent also between 50 and 69 a but not above 70, there seemed to be an effect from background radiation and a trend suggesting an exposure-effect relationship. There was also about a sixfold increase in the rate ratio with regard to solvent exposure, which also seemed to modify the effect of background radiation. Other exposures were associated with relatively modest increases in the rate ratios and/or very small numbers of exposed individuals. It would be worthwhile to undertake further cancer epidemiologic studies of background radiation in which effective study designs are applied and a variety of potential confounders and modifiers of effect are identified and accounted for.

Citations

Jan 1, 1991·American Journal of Industrial Medicine·N E Hall, K D Rosenman
Jan 1, 1987·Pediatric Hematology and Oncology·L L RobisonF L King
Sep 1, 1991·Leukemia·D Henshaw
Nov 5, 1997·Critical Reviews in Toxicology·P Hotz, R R Lauwerys
Jan 1, 1987·American Journal of Industrial Medicine·U FlodinB Persson
Mar 1, 1995·Environmental Health Perspectives·O Axelson
Oct 1, 1995·Occupational and Environmental Medicine·K L HuntingL S Welch
Jan 1, 1985·Scandinavian Journal of Social Medicine·O Axelson
Jan 1, 1990·Leukemia & Lymphoma·N P Lucie
Jan 1, 1985·Medical Oncology and Tumor Pharmacotherapy·L Brandt
Jan 1, 1993·Medical Oncology and Tumor Pharmacotherapy·O Axelson, F Forastiere
Jan 1, 1987·Medical Oncology and Tumor Pharmacotherapy·L Brandt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.